Literature DB >> 31679845

Solid-state analysis of amorphous solid dispersions: Why DSC and XRPD may not be regarded as stand-alone techniques.

Sien Dedroog1, Timothy Pas1, Bjorn Vergauwen2, Christophe Huygens3, Guy Van den Mooter4.   

Abstract

Amorphous solid dispersions (ASDs) are single-phase amorphous systems, where drug molecules are molecularly dispersed (dissolved) in a polymer matrix. The molecular dispersion of the drug molecules is responsible for their improved dissolution properties. Unambiguously establishing the phase behavior of the ASDs is of utmost importance. In this paper, we focused on the complementary nature of (modulated) differential scanning calorimetry ((m)DSC) and X-ray powder diffraction (XRPD) to elucidate the phase behavior of ASDs as demonstrated by a critical discussion of practical real-life examples observed in our research group. The ASDs were manufactured by either applying a solvent-based technique (spray drying), a heat-based technique (hot melt extrusion) or mechanochemical activation (cryo-milling). The encountered limiting factors of XRPD were the lack of sensitivity for small traces of crystallinity, the impossibility to differentiate between distinct amorphous phases and its impossibility to detect nanocrystals in a polymer matrix. In addition, the limiting factors of (m)DSC were defined as the well-described heat-induced sample alteration upon heating, the interfering of residual solvent evaporation with other thermal events and the coinciding of enthalpy recovery with melting events. In all of these cases, the application of a single analytical technique would have led to erroneous conclusions, whilst the combination of (m)DSC and XRPD elucidated the true phases of the ASD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (M)DSC; Amorphous solid dispersions; Cryo-milling; Fenofibrate (3339); Griseofulvin (441140); Hot melt extrusion; Indomethacin (3715); Itraconazole (55283); Ketoconazole (456201); Naproxen (156391); Spray drying; XRPD

Mesh:

Substances:

Year:  2019        PMID: 31679845     DOI: 10.1016/j.jpba.2019.112937

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.

Authors:  Daniel A Davis; Dave A Miller; Supawan Santitewagun; J Axel Zeitler; Yongchao Su; Robert O Williams
Journal:  Int J Pharm X       Date:  2021-07-17

2.  Factors Influencing the Crystallization-Onset Time of Metastable ASDs.

Authors:  Friederike Wolbert; Ineke-Katharina Fahrig; Tobias Gottschalk; Christian Luebbert; Markus Thommes; Gabriele Sadowski
Journal:  Pharmaceutics       Date:  2022-01-23       Impact factor: 6.321

Review 3.  Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design.

Authors:  Julian Quodbach; Malte Bogdahn; Jörg Breitkreutz; Rebecca Chamberlain; Karin Eggenreich; Alessandro Giuseppe Elia; Nadine Gottschalk; Gesine Gunkel-Grabole; Lena Hoffmann; Dnyaneshwar Kapote; Thomas Kipping; Stefan Klinken; Fabian Loose; Tristan Marquetant; Hellen Windolf; Simon Geißler; Tilmann Spitz
Journal:  Ther Innov Regul Sci       Date:  2021-11-26       Impact factor: 1.337

4.  Effects of Polymers on the Drug Solubility and Dissolution Enhancement of Poorly Water-Soluble Rivaroxaban.

Authors:  Min-Jong Choi; Mi Ran Woo; Han-Gon Choi; Sung Giu Jin
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

5.  The Value of Bead Coating in the Manufacturing of Amorphous Solid Dispersions: A Comparative Evaluation with Spray Drying.

Authors:  Eline Boel; Felien Reniers; Wim Dehaen; Guy Van den Mooter
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.